10-K: FutureTech II Acquisition Corp. Details Share Structure, Warrants, and Potential Business Combination in 10-K Filing

FutureTech II Acquisition Corp.'s 10-K filing outlines the company's share structure, warrant details, and ongoing efforts to complete a business combination, including a merger agreement with Longevity Biomedical Inc.

Summary

• FutureTech II Acquisition Corp., a blank check company, filed its 10-K report detailing its financial condition and efforts to find a business combination target.
• The company's authorized capital stock consists of 100,000,000 shares of Class A common stock, 10,000,000 shares of Class B common stock, and 1,000,000 shares of undesignated preferred stock, all with a par value of $0.0001 per share.
• As of April 8, 2025, there were 4,289,961 shares of Class A common stock outstanding, including 779,886 redeemable public shares, 2,875,000 non-redeemable founder shares, 115,000 representative shares, and 520,075 private placement shares.
• The initial stockholders hold approximately 79.14% of the company's issued and outstanding common stock.
• Each warrant entitles the holder to purchase one share of Class A common stock at $11.50 per share, commencing 30 days after the completion of the initial business combination and expiring five years after the completion of the initial business combination.
• The company entered into a merger agreement with Longevity Biomedical Inc. on September 16, 2024, with the intention of completing a business combination.
• The deadline to complete the initial business combination is August 18, 2025.
• The company's securities were suspended from trading on Nasdaq on February 26, 2025, and are now quoted on the over-the-counter market.
• The company intends to make a listing application for the securities of the combined company to be traded on Nasdaq.
• For the year ended December 31, 2024, the company had a net loss of $746,953, which consisted of investment income of $1,342,491, partially offset by expenses of $1,814,864 and tax expense of $274,580.
• As of December 31, 2024, there was $3,537,744 outstanding under the Extension Loans from the Sponsor.
• As of March 31, 2025, there was $3,650,976 outstanding under the Extension Loans from the Sponsor.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the company's net loss, delisting from Nasdaq, and the uncertainty surrounding the completion of the business combination. However, the ongoing efforts to complete the merger and the sponsor's continued support provide some positive aspects.

Positives

• The company has a merger agreement in place with Longevity Biomedical Inc., indicating progress towards a business combination.
• The company intends to relist on Nasdaq after the business combination, which could improve liquidity and visibility.
• The sponsor continues to provide financial support through extension loans, demonstrating commitment to completing a business combination.

Negatives

• The company reported a net loss of $746,953 for the year ended December 31, 2024.
• The company's securities were delisted from Nasdaq on February 26, 2025, which could negatively impact investor sentiment and trading activity.
• The company has a working capital deficit, indicating potential short-term liquidity challenges.

Risks

• The company may not be able to complete the business combination with Longevity Biomedical Inc.
• The company may not be able to relist on Nasdaq after the business combination.
• The company may face challenges in raising additional capital.
• The company's reliance on the sponsor for funding could create conflicts of interest.
• The company's limited operating history and lack of revenue generation create uncertainty about its future prospects.
• The company's securities are now traded over-the-counter, which may reduce liquidity and investor interest.
• The company may be subject to U.S. foreign investment regulations and review by CFIUS, which could delay or prevent a business combination with a U.S. target company.
• The company may be deemed to be an investment company for purposes of the Investment Company Act, which would require burdensome compliance requirements and severely restrict the company's activities.

Future Outlook

The company intends to complete a business combination with Longevity Biomedical Inc. and relist on Nasdaq. The company has until August 18, 2025, to complete the business combination.

Industry Context

The document reflects the challenges faced by SPACs in finding suitable targets and completing business combinations within the given timeframe, as well as the potential impact of regulatory changes and market conditions on these entities.

Comparison to Industry Standards

• The challenges faced by FutureTech II Acquisition Corp. are common among SPACs, particularly in a market with increased regulatory scrutiny and investor caution.
• Comparable companies include other SPACs that have struggled to find suitable targets or have faced delisting from major exchanges.
• The level of sponsor funding through extension loans is comparable to other SPACs seeking to extend their lifespan to complete a deal.
• The redemption rates experienced by FutureTech II Acquisition Corp. are indicative of the broader trend of increased redemptions in the SPAC market.

Related Party Transactions

• The company has an administrative support agreement with the sponsor, paying $10,000 per month for office space and administrative support.
• The sponsor has provided working capital loans to the company.
• The sponsor has provided extension loans to the company to extend the deadline for completing a business combination.

Stakeholder Impact

• Shareholders face the risk of the company not completing a business combination and liquidating, resulting in a loss of investment.
• Shareholders face the risk of the company completing a business combination that is not successful, resulting in a decline in the value of their shares.
• Warrant holders face the risk of the warrants expiring worthless if the company does not complete a business combination.
• The company's employees and service providers face the risk of the company ceasing operations if it does not complete a business combination.

Next Steps

• The company needs to complete the business combination with Longevity Biomedical Inc.
• The company needs to obtain stockholder approval for the business combination.
• The company needs to secure financing for the business combination.
• The company needs to relist on Nasdaq after the business combination.

Key Dates

Keywords

business combination, special purpose acquisition company, SPAC, merger, acquisition, warrants, common stock, redemption, Longevity Biomedical, FutureTech II Acquisition Corp